Whistleblower-initiated enforcement actions against health care fraud and abuse in the United States, 1996 to 2005
- PMID: 18765704
- DOI: 10.7326/0003-4819-149-5-200809020-00009
Whistleblower-initiated enforcement actions against health care fraud and abuse in the United States, 1996 to 2005
Abstract
Federal regulators have aggressively prosecuted health care fraud since the early 1990s, leading to billions of dollars in financial recoveries. Nearly all major cases today are qui tam actions, involving whistleblowers with inside knowledge of the allegedly illegal schemes. This article documents the outcomes of major enforcement actions and describe the schemes, defendants, and whistleblowers involved. The authors obtained an inventory of unsealed federal qui tam litigation targeting health care fraud that was resolved between 1996 and 2005 from the U.S. Department of Justice and gathered further information from publicly available sources. Among 379 cases, $9.3 billion was recovered, with more than $1.0 billion paid to whistleblowers. Case frequency peaked in 2001, but annual recoveries increased sharply from 2002 to 2005. Whistleblowers were frequently executives or physicians, and 75% were employees of defendant organizations. The 13 (4%) cases against pharmaceutical companies accounted for $3.6 billion (39%) of total recoveries. This study illuminates the scope and characteristics of qui tam fraud litigation and the whistleblowers who animate this important tool for addressing waste in the health care sector.
Similar articles
-
Implementing US-style anti-fraud laws in the Australian pharmaceutical and health care industries.Med J Aust. 2011 May 2;194(9):474-8. doi: 10.5694/j.1326-5377.2011.tb03066.x. Med J Aust. 2011. PMID: 21534908
-
Qui tam litigation: "whistleblower" lawsuits.Manag Care Interface. 2000 Apr;13(4):90-2, 99. Manag Care Interface. 2000. PMID: 11066290
-
Whistleblowers: there ain't no cure, but there is prevention.J Med Pract Manage. 2006 Sep-Oct;22(2):69-70. J Med Pract Manage. 2006. PMID: 17181004
-
Fraud and abuse. Federal civil health care litigation and settlement.J Leg Med. 1998 Mar;19(1):1-62. doi: 10.1080/01947649809511052. J Leg Med. 1998. PMID: 9564094 Review. No abstract available.
-
Caveat medicus: consequences of federal investigations of marketing activities of pharmaceutical suppliers of prostate cancer drugs.J Clin Oncol. 2005 Dec 1;23(34):8894-905. doi: 10.1200/JCO.2005.01.4605. J Clin Oncol. 2005. PMID: 16314650 Review.
Cited by
-
Transparency interventions to improve health system outcomes in low and middle-income countries: a narrative systematic review.BMJ Open. 2024 Jun 6;14(6):e081152. doi: 10.1136/bmjopen-2023-081152. BMJ Open. 2024. PMID: 38844391 Free PMC article.
-
What are people's attitudes toward medical insurance fraud whistleblowers? a study from China.BMC Public Health. 2024 Jan 3;24(1):82. doi: 10.1186/s12889-023-17606-3. BMC Public Health. 2024. PMID: 38172753 Free PMC article.
-
What influences the public's willingness to report health insurance fraud in familiar or unfamiliar healthcare settings? a cross-sectional study of the young and middle-aged people in China.BMC Public Health. 2024 Jan 2;24(1):24. doi: 10.1186/s12889-023-17581-9. BMC Public Health. 2024. PMID: 38166821 Free PMC article.
-
The Public's Self-Avoidance and Other-Reliance in the Reporting of Medical Insurance Fraud: A Cross-Sectional Survey in China.Risk Manag Healthc Policy. 2023 Dec 22;16:2869-2881. doi: 10.2147/RMHP.S438854. eCollection 2023. Risk Manag Healthc Policy. 2023. PMID: 38149180 Free PMC article.
-
Why Not Blow the Whistle on Health Care Insurance Fraud? Evidence from Jiangsu Province, China.Risk Manag Healthc Policy. 2022 Oct 12;15:1897-1915. doi: 10.2147/RMHP.S379300. eCollection 2022. Risk Manag Healthc Policy. 2022. PMID: 36268183 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical